ArticleFood science & nutrition2025
Renoprotective Role and Mechanisms of Luteolin in Chronic Kidney Disease: Insights From NHANES Data, Network Pharmacology, Mendelian Randomization, and Molecular Docking Techniques.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the renoprotective properties of flavonoids are well established in chronic kidney disease (CKD), further investigation is required to identify the most efficacious compound of flavonoids and to elucidate the underlying mechanisms. This study identified the most advantageous compound of flavonoids for CKD using data from the National Health and Nutrition Examination Survey (NHANES) database and investigated underlying mechanisms through mediation analysis, network pharmacology, bioinformatics analysis, Mendelian randomization (MR), and molecular docking techniques. Our research discovered that flavones, including luteolin and apigenin, played a crucial role in reducing the risk of CKD. The intake of apigenin, luteolin, and total flavones was all significantly associated with the risk reduction of CKD. We observed a nonlinear correlation between the luteolin intake and CKD risk, with the optimal daily intake identified as 1.36 mg. Then, we identified luteolin as the most important compound for kidney protection. Mediation effect analysis showed that luteolin might reduce CKD risk by regulating inflammation, serum uric acid, albumin, and bicarbonate. We identified 234 overlapping genes between luteolin and CKD, with enrichment analysis indicating their association with cellular metabolism, inflammation, oxidative stress, and immune responses. Additionally, we identified TP53, HSP90AA1, IL6, and ESR1 as the four hub genes, with HSP90AA1 identified as a risk target for CKD through MR analysis. Molecular docking techniques showed a strong binding affinity between luteolin and HSP90AA1. This study identified luteolin as a key flavonoid linked to lower CKD risk and suggested HSP90AA1 as a potential molecular target mediating its renoprotective effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.